Social Media Monitoring on Aliqopa: Research and Study on Social Media Channels

Social Media Listening report on Aliqopa drug from Bayer healthcare Pharmaceuticals got US FDA approval for Relapsed/Refractory Follicular Lymphoma

Research Study Background

On 14^th September 2017 FDA approves Bayer’s Aliqopa (copanlisib) for the treatment of Relapsed or Refractory Follicular Lymphoma. Aliqopa is a Kinase inhibitor that works against PI3K-alpha and PI3K-delta isoforms expressed in malignant B cells. Aliqopa got accelerated approval was on the basis of Phase-2 CHRONOS-1 study where Copanlisib has shown Overall Response Rate (59%) in patients with relapsed Follicular Lymphoma. Formerly FDA had approved copanlisib profligate track designation in Follicular Lymphoma as well as Orphan Drug designation for the treatment of patients with Follicular Lymphoma

1. Study was conducted to understand initial social media reaction on Aliqopa where total 463 online posts were analysed by our subject matter experts.
2. Study monitoring period was considered from 1^st Sep – 28^th Sep 2017.

Findings:

1. “HCPs, Patients, News, Advocacy groups and Caregivers sharing information on approval of Aliqopa on various Social Media Channels
2. Twitter followed by blogs and Mainstream having maximum volume of conversation.
3. Positive posts tracked around Aliqopa approval which says- “FDA grants accelerated approval to Aliqopa (copanlisib) for the treatment of adult’s w/relapsed follicular lymphoma”.

Sentiment Analysis on Aliqopa Drug Approval

Positive: Aliqopa approval was quoted as an Impressive breakthrough - “Bayer’s Aliqopa Wins Accelerated Approval”- Pharmacist (NYRXMAN)

Neutral: Majority of healthcare practitioners and patients were either neutral or positive about the approval, efficacy and found sharing the information on social media platform- “FDA approves Copanlisib (PI3Ki) for relapsed follicular lymphoma”- HCP (DRANASYOUNES)

Contact us for qualitative social media monitoring and social media intelligence research/reports.